

# CUROS<sup>®</sup>

## Port Protector



The CuroS<sup>®</sup> patented design complies with 2011 INS Standards of Practice specifying the security of luer-locks on all "add-on" devices.

### The CuroS<sup>®</sup> Port Protector Simply Changing Infection Control

The CuroS<sup>®</sup> Port Protector is a simple, innovative, disposable medical device that guards against infection by keeping luer-activated needleless valve access ports protected and clean.

Dramatically more effective than a standard alcohol swab in reducing bacterial counts,\* CuroS is clinician preferred for safeguarding patients from bloodstream infections.

*Green is Clean*  
**Use CUROS<sup>®</sup>**

\*Tests conducted at an independent laboratory confirmed CuroS achieved -5 log reduction in bacterial counts compared to -3 log reduction with a standard alcohol swab. A summary of these studies is available on request.

**IVERA<sup>™</sup>**  
Solutions for a New Era in Infection Control<sup>™</sup>

Ivera Medical Corporation • [www.iveramed.com](http://www.iveramed.com)

## Impact of Alcohol Impregnated Port Protectors and Needleless Neutral Pressure Connectors on Central Line-Associated Blood Stream Infections and Contamination of Blood Cultures in an Inpatient Oncology Unit.

Michael A. Sweet, Pharm.D., BCPS | West Virginia University Hospitals, Morgantown, WV

### NEW PRODUCT EVALUATION POSTER | SHEA ANNUAL SCIENTIFIC MEETING 2011

**Study:** Evaluate the impact on CLABSI and contaminated blood cultures as a result of exchanging hub swabbing procedure with alcohol impregnated port protectors on all central venous catheters.

**Location:** 12-bed blood and marrow transplant and 20-bed oncology units.

**Results:** **Infection Rate:** During the control period, there were 895 admissions contributing 5,494 line days and 16 infections (2.9 infections/1000 central line days). During the intervention period, there were 475 admissions with 2,493 line days and 1 infection (0.4 infections/1000 central line days) (P=0.0318).

**Contaminated Blood Cultures:** The rate of contaminated blood cultures from central lines was 2.5% (17/692) and 0.2% (1/470) during the control and intervention period (P= 0.002), respectively.

Results:	Control Alcohol Swabbing Jan-Dec 2009	Curos® Port Protectors Jan-Jul 2010	%
Infections/1000 Central-line days	2.9	0.4	86.2%
% contaminated blood cultures	2.5%	0.2%	92.0%

**Compliance:** The rate of **compliance was >85%** for the study period.

**Cost Avoidance:** Estimated annualized costs associated with CLABSI and contaminated blood cultures were \$565,000 in the control period. Costs were reduced to \$65,000 during the intervention, resulting in a projected **cost avoidance of \$500,000.**

**Conclusions:** The implementation of an alcohol-impregnated port protector and needleless neutral-pressure connector significantly reduced the rate of CLABSI in our oncology population. In addition, the rate of contaminated blood cultures was significantly reduced. **This intervention was easily introduced, with a high rate of compliance and significant cost reduction to our hospital.**

